

Imaging-based phenotypic profiling for high-throughput chemical screening at the U.S. Environmental Protection Agency

Johanna Nyffeler

ORISE post-doctoral participant

Center for Computational Toxicology & Exposure, Office of Research & Development, U.S. Environmental Protection Agency

ORCID 0000-0002-6155-9743


Nyffeler.Johanna@epa.gov

The views expressed in this presentation are those of the author and do not necessarily reflect the views or policies of the U.S. EPA.


Introduction: Dr. Johanna Nyffeler



- BSc in Biochemistry, MSc in Genetics
- **PhD at University of Konstanz, Germany**
 - group of Dr. Marcel Leist
 - development of high-content assays for *in vitro* developmental neurotoxicology



- **PostDoc at Center for Computational Toxicology & Exposure (CCTE), US EPA**
 - group of Dr. Joshua Harrill
 - high-throughput image-based profiling ('Cell Painting'), computational toxicology



1. **What is imaging-based phenotypic profiling?**
2. **Implementation at CCTE/EPA**
3. **Aims/Focus for CCTE/EPA**
4. **Application 1: Potency estimation**
5. **Application 2: Mechanistic prediction**


What is Imaging-Based Phenotypic Profiling?

- labeling of various cell organelles with fluorescent probes in *in vitro* cultures
- assessing a large variety of morphological features on individual cells

'Cell Painting' assay

Gustafsdottir *et al.* 2013

Bray *et al.* 2016



Flourescent labels	
DNA:	H-33342
RNA:	SYTO14
ER:	Concanavalin A-488
Actin:	Phalloidin-568
Golgi + Membrane:	wheat germ agglutinin (WGA) -555
Mitochondria:	MitoTracker

shape

intensity



localization

texture

1300 features per cell



profile

for each chemical x concentration

Nyffeler *et al.* 2020



Cell Painting = Phenotypic Profiling

High-Throughput Phenotypic Profiling = HTPP

Example Chemicals: Qualitative Observation

Solvent control (0.5% DMSO)



Berberine chloride (10 μ M)



→ Mitochondrial
compactness/texture

Solvent control (0.5% DMSO)

Etoposide (3 μ M)



→ Cells are larger

⇒ **Strong phenotypes are observable qualitatively**

adapted from Nyffeler *et al.* (2020)
Toxicol Appl Pharmacol.
PMID: 31899216

Implementation at CCTE/EPA

Laboratory Workflow







Image Analysis Workflow → Image Segmentation





1. find nuclei



2. find cell outline




3. reject border objects




Define Cellular Compartments


nuclei




cytoplasm



membrane



ring



cell







Image Processing


Profiling
with PerkinElmer
Harmony Software



= 1300 features
per cell

With illustrations from Perkin Elmer

Example Chemicals: Quantitative Observation



⇒ Qualitative observations can be quantified

adapted from Nyffeler *et al.* (2020)
Toxicol Appl Pharmacol.
PMID: 31899216

Aim for CCTE/EPA


Tiered Hazard Evaluation Strategy based on New Approach Methods (NAMs)

Profiling Assays

- untargeted
- measure large number of endpoints (e.g., transcripts, phenotypic features)
- high-throughput transcriptomics (**HTTr**) (Harrill et al. 2021, PMID: 33538836)
- high-throughput phenotypic profiling (**HTPP**) (Nyffeler et al. 2020, PMID: 31899216)

Focus

- Prioritization: False positives are preferred over false negatives





adapted from “The Next Generation Blueprint of Computational Toxicology at the U.S. EPA”, Tox. Sci. 2019; 169(2):317-322. PMID: 30835285

Challenges of Environmental Chemicals


- Often low expected bioactivity
 - Often lack a specific molecular target in human-based cell models
 - ‘Poly-pharmacology’
 - Responses can be associated with general cell stress
- ⇒ **more challenging for hit identification than drug-like chemicals**

Two Applications




← profile

for each chemical x concentration




Application 1

concentration-response modelling




Application 2

Chemical A



Biological similarity

Chemical B




Potency estimation:
in vitro point-of-departure (POD)

- Nyffeler *et al.* (2020) Toxicol Appl Pharmacol. PMID: 31899216
- Willis *et al.* (2020). SLAS Discov. PMID: 32546035
- Nyffeler *et al.* (2021). SLAS Discov. PMID: 32862757

Compare profiles with annotated reference chemicals
→ putative mechanisms

work in progress

Application 1: Potency Estimation



U-2 OS ToxCast Screen Experimental Design


Parameter	Multiplier	Notes
Cell Type(s)	1	U-2 OS
Time Points:	1	24 hours
Chemicals	1,202	TSCA Chemicals of interest to US EPA <ul style="list-style-type: none"> Includes 462 APCRA case study chemicals Includes 179 chemicals with annotated molecular targets
Concentrations:	8	3.5 log ₁₀ units; ~half-log ₁₀ spacing
Biological Replicates:	4	--



Reference chemicals run on each plate

	Chemical	Molecular Target	Tested Range
Weak	Dexamethasone	Glucocorticoid receptor agonist	0.001 – 3 µM
Medium	all-trans-Retinoic Acid	Retinoic acid receptor agonist	0.0003 – 1 µM
Strong	Etoposide	DNA topoisomerase inhibitor	0.03 - 10 µM
Extra strong	Trichostatin A	Histone deacetylase inhibitor	1 µM



Reproducibility: Potencies



⇒ Potency estimates vary less than ½ an order of magnitude

HTPP Screening Results (1)


Active chemicals:




- ⇒ ~ 40% of chemicals were active
- ⇒ Most activity is > 10 μ M
- ⇒ Chemicals active in HTPP are more often active in many ToxCast assays

HTPP Screening Results (2)

Comparison with ToxCast screening results:




⇒ HTPP with a single cell line less sensitive than all ToxCast assays combined....




⇒ ... but more sensitive than the ToxCast cytotoxicity burst estimate

Comparison to *in vivo* Effect Values

- 303 chemicals were active and had pharmacokinetic (PK) information




POD: point-of-departure
AED: administered equivalent dose




⇒ **78% of HTPP AED are within 2 orders of magnitude of the *in vivo* POD**

Comparison to Exposure Estimates

POD: point-of-departure
AED: administered equivalent dose




Potential for humans
to be exposed to
bioactive concentrations



- ⇒ for 49% of chemicals, predicted exposure is > 1000x lower than estimated bioactivity
- ⇒ for a small set of chemicals, the BER was negative, indicating a potential for humans to be exposed to bioactive concentrations of these chemicals

Application 2: Mechanistic Prediction



Feature Selection & Profile Comparison


Feature Selection

1300 features



1. remove features that do not provide any information (i.e. have 0 variance)
2. remove features that are not reproducible (high variation between treatments of different biological replicates)
3. remove features that are highly correlated (using recursive feature elimination)

317 features

Profile Comparison



Reproducibility: Phenotypic Profiles




⇒ Phenotypic profiles are highly reproducible across different plates

Hypothesis: Chemicals with similar mechanisms will display similar profiles.


Example: Nuclear Receptor Modulators (I)

- 52 chemicals were annotated as targeting a nuclear receptor

Biological similarity in HTPP



Gene expression in U-2 OS



target



Agonists of the GR and of RAR/RXR display characteristic profiles




Expression of a target does not guarantee that characteristic profiles are observed (e.g., PPAR)

Example: Nuclear Receptor Modulators (II)


target



Comparison to ToxCast potencies




Gene expression in U-2 OS



- ⇒ For two receptor systems that are expressed (GR, RAR/RXR) potencies were comparable with ToxCast
- ⇒ For receptors with no/low expression in this cell line, HTPP was less sensitive than ToxCast

Pharmacological Blockade of Phenotypic Effects




- ⇒ RAR but not RXR antagonists block the retinoid phenotype
- ⇒ Phenotypic profile is related to RAR activation


Application: Find Retinoid-like Chemicals

1. Compare profiles to 5 known retinoids:

→ 10 candidate chemicals




2. Repeat HTPP experiments:



3. Compare to ToxCast results:



known retinoids



→ Flutolanil had activity in ToxCast assays targeting RAR/RXR


⇒ HTPP has the potential to identify environmental chemicals with specific activities

Specific vs Non-specific Phenotypes




Application: Grouping of Conazoles

- group of fungicides
- disturb ergosterol synthesis via CYP51 and CYP61 (target absent in mammals)




- ⇒ most conazoles are phenotypically similar
- ⇒ Diniconazole is phenotypically different from the other active conazoles

Conclusions



Application 1: Potency estimation

- HTPP can be used to derive *in vitro* potency estimates
- These *in vitro* potency estimates are often comparable and sometimes more conservative than *in vivo* PODs



Application 2: Mechanistic prediction

- Similar mechanisms → similar phenotypes

- **Combine HTPP with HTTr**
 - compare results, both in terms of potencies and mechanisms
 - increased potential to discern molecular mechanisms

- **Expand Coverage of Biological Space**
 - deploy assay across diverse cell lines that express different receptors/pathways
 - proof-of-concept (Gustafsdottir *et al.* 2013, Willis *et al.* 2020)
 - expansion to other species

Acknowledgements



Office of Research and Development (ORD) Center for Computational Toxicology and Exposure (CCTE)

Harrill Lab team

- **Joshua Harrill**
- **Clinton Willis**
- **Felix Harris**
- Rick Brockway
- Megan Culbreth
- Dan Hallinger
- Terri Fairley

Data analysis

- Daniel Chang
- Kathy Coutros
- Logan Everett
- Derik Haggard
- Richard Judson
- Ryan Lougee
- Grace Patlewicz
- Katie Paul Friedman
- Ann Richard
- Woody Setzer
- Imran Shah
- John Wambaugh



National Toxicology Program
U.S. Department of Health and Human Services

- Scott Auerbach